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R E B U T T A L  
James Woods • Gall Winger 
Rebuttal of comments by Griffiths, Lader and Greenblatt 
to Review by Woods and Winger 
Dr Griffiths curiously reiterates points we have made 
repeatedly and implies that we have failed to make 
them. Our first review on benzodiazepines (Woods et al. 
1987) noted that, in terms of the volume of drugs dis- 
pensed, most use is by chronic users; but we consider 
it more important to count people rather than pills, 
and we stand by our point that most actual use of ben- 
zodiazepines is appropriate. Also, we have emphasized 
the need for study of the effects of long-term use in 
each of our publications about benzodiazepines 
(Woods et al. 1987, 1988, 1992), including our article 
in this issue. 
It does a great disservice to chronic users of pre- 
scribed benzodiazepines to label them as drug addicts. 
The vast majority of users are following their physi- 
cians' orders. Benzodiazepine users tend to decrease 
use over time (Woods et al. 1987); this too differs from, 
e.g., chronic daily nicotine use, which typically results 
from many years of  increasing use (Shiffman 1989; 
DHHS 1991). Benzodiazepine users also differ from 
addicts in that, after discontinuing use, they are unlikely 
to think about or wish to resume taking the drugs 
(Lucki et al. 1991). 
In this issue and previously (Woods et al. 1987, 1988, 
1992), we have considered the evidence for and impli- 
cations of the preference for benzodiazepines among 
polydrug abusers. But we do not agree with Drs. 
Griffiths or Lader that this is "the important point" or 
that it reflects "a high abuse potential" in any accept- 
able use of the term; we believe the relatively impor- 
tant point is that most patients with anxiety or 
insomnia are not at risk of abusing benzodiazepines. 
Dr. Lader makes several very specific points for 
which he offers little substantiation. He notes "increas- 
ing evidence" that "non-drug treatments are at least as 
effective" as and safer than benzodiazepines for mild 
anxiety or insomnia, but cites only a single, 10-year- 
old reference. We doubt that current, non-drug treat- 
ment is a practical alternative for even the majority of 
patients. Dr. Lader offers no references for his asser- 
tion that "severely anxious patients and those with 
panic attacks respond better to antidepressants". Most 
of the relevant studies of panic disorder have compared 
alprazolam with imipramine, and have found the drugs 
equivalent in effectiveness (Hollister et al. 1993; 
Rosenberg 1993). 
We know of no-one besides Dr. Lader who would 
suggest that, by referring to "physiological" depen- 
dence, we meant to imply "some element of normal- 
ity". He emphasizes that benzodiazepine withdrawal 
can be intolerable, but takes issue with our point that 
discontinuation by tapering the dose can minimize this 
discomfort. For support, he cites Schweitzer et al. 
(1990), who, however, made exactly our point, and who 
found that withdrawal reactions following gradual 
taper were "rarely more than mild to moderate" 
(Schweitzer et al. 1990). 
Dr. Greenblatt suggests correctly that, from a 
scientific perspective, we are guilty of oversimplification 
in choosing to refer to the duration of action of drugs 
as if this were equivalent to half-life. For many 
researchers as well as clinicians, the options for chang- 
ing effect with a particular benzodiazepine are limited 
to manipulating dose and/or frequency of administra- 
tion. Information about the pharmacokinetic parame- 
ters described by Dr. Greenblatt would surely improve 
many of our judgements; regrettably, this level of 
sophistication remains beyond the vast majority of us. 
J. Woods (~;~) ' G. Winger 
Department of Pharmacology, University of Michigan Medical 
School, 6322 Medical Science Building, Ann Arbor, 
MI 48109-0626, USA 
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